Principal Coordinates Analysis (PCoA) of gut bacterial (A) and fungal (B) communities in <i>C. capitata.</i> by Maria Cecilia Rasuk (4594303)

The 44 study forests in relation to elevation, distance to population center, and the presence of a wall. by Catherine L. Cardelús (6429320)

A2PP inhibits <i>M</i>. <i>hyorhinis</i> infection. by Shiqin Yuan (848670)

A2PP reduces <i>M</i>. <i>hyorhinis</i> infection. by Shiqin Yuan (848670)

The volume ratio of the endoplasmatic reticulum (ER) as a function of the surface volume ratio (SVR). by Franziska Oschmann (3743797)

Results of a simulation by the Gillespie algorithm. by Kouki Uchinomiya (16350276)

The raw data for Fig 8A. by Hongjoo An (21703199)

“…Sox10 (SRY-box containing gene 10) is a high-mobility group transcription factor that orchestrates the development of OLs. …”

Example protocol of a testing session. by Steven A. Thompson (22477818)

S1A Fig raw image. by Rachel K. Meade (22216529)

“…Here, we identify cathepsin Z (<i><i>Ctsz</i></i>) as a lead candidate underlying this TB susceptibility and show that <i><i>Ctsz</i></i> ablation leads to increased bacterial burden, pulmonary inflammation and decreased survival in mice. …”

Behavioural data from Study A. by Jasmine Heurlin (18501279)

“…In addition, human walking positively influenced eye contact behaviour while simultaneously decreasing exploration behaviour. In study C, a group of six socialised pack-living wolves and six similarly socialised pack-living dogs were tested after the <i>Ignore</i> treatment. …”

Establishment of a diabetic rat model. by Lan Zeng (638254)

“…In addition, RP11-502I4.3 expression was decreased in the retinas of diabetic rats compared with non-diabetic rats (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0312791#pone.0312791.g003" target="_blank">Fig 3B</a>), and it was predominantly localised in the cytoplasm (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0312791#pone.0312791.g003" target="_blank">Fig 3C</a>).…”

Effects of EFT manipulation on explicit measures. by Cinzia Calluso (5662420)

S4 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S1 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S5 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S3 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S6 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S2 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”

S1 Data - by R. J. S. D. Heine (17889199)

“…</p><p>Methods</p><p>The model was used to calculate cumulative yearly prices, cumulative prices per indication, and non-cumulative indication-based prices using inputs such as research and development (R&D) costs, manufacturing costs, eligible patient population, and a profit margin. A deterministic stepwise analysis and scenario analysis were conducted to examine how sensitive the estimated price is to the different input assumptions.…”